Literature DB >> 22018018

Normal and malignant megakaryopoiesis.

Qiang Wen1, Benjamin Goldenson, John D Crispino.   

Abstract

Megakaryopoiesis is the process by which bone marrow progenitor cells develop into mature megakaryocytes (MKs), which in turn produce platelets required for normal haemostasis. Over the past decade, molecular mechanisms that contribute to MK development and differentiation have begun to be elucidated. In this review, we provide an overview of megakaryopoiesis and summarise the latest developments in this field. Specially, we focus on polyploidisation, a unique form of the cell cycle that allows MKs to increase their DNA content, and the genes that regulate this process. In addition, because MKs have an important role in the pathogenesis of acute megakaryocytic leukaemia and a subset of myeloproliferative neoplasms, including essential thrombocythemia and primary myelofibrosis, we discuss the biology and genetics of these disorders. We anticipate that an increased understanding of normal MK differentiation will provide new insights into novel therapeutic approaches that will directly benefit patients.

Entities:  

Mesh:

Year:  2011        PMID: 22018018      PMCID: PMC4869998          DOI: 10.1017/S1462399411002043

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  169 in total

1.  Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

Authors:  R Jäger; H Gisslinger; F Passamonti; E Rumi; T Berg; B Gisslinger; D Pietra; A Harutyunyan; T Klampfl; D Olcaydu; M Cazzola; R Kralovics
Journal:  Leukemia       Date:  2010-05-27       Impact factor: 11.528

Review 2.  Nineteen cases of the t(1;22)(p13;q13) acute megakaryblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group.

Authors:  J Bernstein; N Dastugue; O A Haas; J Harbott; N A Heerema; J L Huret; J Landman-Parker; M M LeBeau; C Leonard; G Mann; M P Pages; C Perot; H Pirc-Danoewinata; B Roitzheim; C M Rubin; M Slociak; F Viguie
Journal:  Leukemia       Date:  2000-01       Impact factor: 11.528

3.  Primitive erythropoiesis and megakaryopoiesis in the yolk sac are independent of c-myb.

Authors:  Joanna Tober; Kathleen E McGrath; James Palis
Journal:  Blood       Date:  2008-01-03       Impact factor: 22.113

4.  Endomitosis of human megakaryocytes are due to abortive mitosis.

Authors:  N Vitrat; K Cohen-Solal; C Pique; J P Le Couedic; F Norol; A K Larsen; A Katz; W Vainchenker; N Debili
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

5.  Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.

Authors:  Yubin Ge; Alan A Dombkowski; Katherine M LaFiura; Dana Tatman; Ravikiran S Yedidi; Mark L Stout; Steven A Buck; Gita Massey; David L Becton; Howard J Weinstein; Yaddanapudi Ravindranath; Larry H Matherly; Jeffrey W Taub
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

6.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

Authors:  Stephen T Oh; Erin F Simonds; Carol Jones; Matthew B Hale; Yury Goltsev; Kenneth D Gibbs; Jason D Merker; James L Zehnder; Garry P Nolan; Jason Gotlib
Journal:  Blood       Date:  2010-04-19       Impact factor: 22.113

7.  TAp73alpha binds the kinetochore proteins Bub1 and Bub3 resulting in polyploidy.

Authors:  Patrizia Vernole; Michael H Neale; Daniela Barcaroli; Eliana Munarriz; Richard A Knight; Richard Tomasini; Tak W Mak; Gerry Melino; Vincenzo De Laurenzi
Journal:  Cell Cycle       Date:  2009-02-12       Impact factor: 4.534

8.  Erythroblast transformation by FLI-1 depends upon its specific DNA binding and transcriptional activation properties.

Authors:  Sabine Ano; Rui Pereira; Martine Pironin; Isabelle Lesault; Caroline Milley; Ingrid Lebigot; Christine Tran Quang; Jacques Ghysdael
Journal:  J Biol Chem       Date:  2003-10-21       Impact factor: 5.157

9.  Survivin is not required for the endomitotic cell cycle of megakaryocytes.

Authors:  Qiang Wen; Cindy Leung; Zan Huang; Sara Small; Alagarsamy Lakku Reddi; Jonathan D Licht; John D Crispino
Journal:  Blood       Date:  2009-04-01       Impact factor: 22.113

10.  Different sequence requirements for expression in erythroid and megakaryocytic cells within a regulatory element upstream of the GATA-1 gene.

Authors:  P Vyas; M A McDevitt; A B Cantor; S G Katz; Y Fujiwara; S H Orkin
Journal:  Development       Date:  1999-06       Impact factor: 6.868

View more
  10 in total

1.  Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.

Authors:  Marco Pizzi; Richard T Silver; Ariella Barel; Attilio Orazi
Journal:  Mod Pathol       Date:  2015-08-14       Impact factor: 7.842

2.  Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.

Authors:  E Masselli; C Carubbi; G Gobbi; P Mirandola; D Galli; S Martini; S Bonomini; M Crugnola; L Craviotto; F Aversa; M Vitale
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

3.  Abivertinib inhibits megakaryocyte differentiation and platelet biogenesis.

Authors:  Jiansong Huang; Xin Huang; Yang Li; Xia Li; Jinghan Wang; Fenglin Li; Xiao Yan; Huanping Wang; Yungui Wang; Xiangjie Lin; Jifang Tu; Daqiang He; Wenle Ye; Min Yang; Jie Jin
Journal:  Front Med       Date:  2021-11-18       Impact factor: 9.927

4.  Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.

Authors:  Qiang Wen; Benjamin Goldenson; Serena J Silver; Monica Schenone; Vlado Dancik; Zan Huang; Ling-Zhi Wang; Timothy A Lewis; W Frank An; Xiaoyu Li; Mark-Anthony Bray; Clarisse Thiollier; Lauren Diebold; Laure Gilles; Martha S Vokes; Christopher B Moore; Meghan Bliss-Moreau; Lynn Verplank; Nicola J Tolliday; Rama Mishra; Sasidhar Vemula; Jianjian Shi; Lei Wei; Reuben Kapur; Cécile K Lopez; Bastien Gerby; Paola Ballerini; Francoise Pflumio; D Gary Gilliland; Liat Goldberg; Yehudit Birger; Shai Izraeli; Alan S Gamis; Franklin O Smith; William G Woods; Jeffrey Taub; Christina A Scherer; James E Bradner; Boon-Cher Goh; Thomas Mercher; Anne E Carpenter; Robert J Gould; Paul A Clemons; Steven A Carr; David E Root; Stuart L Schreiber; Andrew M Stern; John D Crispino
Journal:  Cell       Date:  2012-08-03       Impact factor: 41.582

Review 5.  The role of TGFβ in hematopoiesis and myeloid disorders.

Authors:  Alex Bataller; Guillermo Montalban-Bravo; Kelly A Soltysiak; Guillermo Garcia-Manero
Journal:  Leukemia       Date:  2019-02-28       Impact factor: 11.528

Review 6.  The aurora kinases in cell cycle and leukemia.

Authors:  B Goldenson; J D Crispino
Journal:  Oncogene       Date:  2014-03-17       Impact factor: 9.867

7.  Cytosolic carboxypeptidase CCP6 is required for megakaryopoiesis by modulating Mad2 polyglutamylation.

Authors:  Buqing Ye; Chong Li; Zhao Yang; Yanying Wang; Junfeng Hao; Li Wang; Yi Li; Ying Du; Lu Hao; Benyu Liu; Shuo Wang; Pengyan Xia; Guanling Huang; Lei Sun; Yong Tian; Zusen Fan
Journal:  J Exp Med       Date:  2014-10-20       Impact factor: 14.307

8.  Prognostic significance of mutated genes in megakaryocytic disorders.

Authors:  Ali Amin Asnafi; Mohammad Bagher Mohammadi; Hadi Rezaeeyan; Nader Davari; Najmaldin Saki
Journal:  Oncol Rev       Date:  2019-07-22

9.  Runx1 and Runx2 inhibit fibrotic conversion of cellular niches for hematopoietic stem cells.

Authors:  Yoshiki Omatsu; Shota Aiba; Tomonori Maeta; Kei Higaki; Kazunari Aoki; Hitomi Watanabe; Gen Kondoh; Riko Nishimura; Shu Takeda; Ung-Il Chung; Takashi Nagasawa
Journal:  Nat Commun       Date:  2022-05-12       Impact factor: 17.694

10.  Phosphorylation of ribosomal protein S6 kinase 1 at Thr421/Ser424 and dephosphorylation at Thr389 regulates SP600125-induced polyploidization of megakaryocytic cell lines.

Authors:  Chang-Ling Li; Jin-Gang Yang; Di Lin; Yong-Shan Zhao; Shuo Liu; Si-Ning Xing; Song Zhao; Cong-Qin Chen; Zhi-Ming Jiang; Fei-Fei Pu; Jian-Ping Cao; Dong-Chu Ma
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.